News | May 29, 2012

Cianna Medical Launches Online Physician Resource for Breast Brachytherapy

May 29, 2012 — Cianna Medical, maker of the SAVI breast brachytherapy applicator, recently announced the launch of BEST (Brachytherapy Efficacy, Safety and Treatment) Forum, a new educational resource for physicians to obtain the latest research in breast brachytherapy and gain insights into best practices and available technology.

Both online and in person, BEST Forum brings together thought leaders in the field of breast cancer care to discuss their extensive experiences and research in brachytherapy, treatment and clinical outcomes. Breast brachytherapy is a form of accelerated partial breast irradiation (APBI), a shortened course of radiation therapy for early-stage breast cancer patients following lumpectomy surgery.

At the BEST Forum website, which launched in early May, physicians can view presentations from brachytherapy experts, as well as download white papers, presentation slides and supporting clinical data, and register for future presentations.

"We're excited to introduce this unique resource, as it enables physicians interested in breast brachytherapy to learn from their colleagues' experiences while providing them with the tools to educate referring physicians in their own communities about the benefits of this accelerated treatment option," said Jill Anderson, president and CEO of Cianna Medical.

Volume 1 of BEST Forum features radiation oncologist Robert Kuske, M.D., FAACE, from Arizona Breast Cancer Specialists in Scottsdale, Ariz. In Practical Application of Patient Selection Criteria, Kuske discusses the origin and common misconceptions regarding current patient selection guidelines from the American Society of Radiation of Oncology (ASTRO) for the use of APBI.

In addition to discussing his own experiences, Kuske reviews emerging data on APBI, focused on controversial subsets such as women with estrogen receptor (ER) negative tumors, ductal carcinoma in situ (DCIS) and younger age (<60 years). Kuske also explains how strut-based brachytherapy can expand the ability to treat eligible patients where anatomical restrictions prevent the use of other forms of breast brachytherapy.

Volume 2, Lower Toxicities with Strut-based Brachytherapy: 4-year Results, is scheduled to be released in July. Catheryn Yashar, M.D., a radiation oncologist at UC San Diego Moores Cancer Center in La Jolla, Calif., will provide an in-depth analysis on published data from the SAVI Collaborative Research Group, including acute and late toxicity, local recurrence rates and how strut-based brachytherapy can expand patient eligibility for APBI.

The published data has been presented at several medical conferences in 2012, including the American College of Radiation Oncology (ACRO), the American Society of Breast Disease (ASBD) and the American Brachytherapy Society (ABS) World Congress of Brachytherapy.

For more information: www.thebestforum.com

Related Content

Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Cleveland Clinic Leads Development of New Guidelines for Radiation in Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 31, 2017
October 31, 2017 — Cleveland Clinic researcher Chirag Shah, M.D., recently led the development of updated guidelines
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Pelvic Radiation Confirmed as Standard of Care for High-Risk, Early-Stage Endometrial Cancer
News | Brachytherapy Systems, Women's Healthcare | September 28, 2017
In a new phase III trial report, recurrence-free and overall survival rates for women with stage I-II high-risk...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System
News | Brachytherapy Systems, Women's Healthcare | May 01, 2017
iCAD Inc. announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation...
New Clinical Data on Xoft System Presented at American Brachytherapy Society Annual Meeting
News | Brachytherapy Systems, Women's Healthcare | April 20, 2017
iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft...
Concure Oncology, Breast Microseed Treatment, one day, low-dose rate brachytherapy, LDR
Technology | Brachytherapy Systems, Women's Healthcare | May 12, 2016
Concure Oncology/Breast Microseed Inc. announced the launch of its one-time, one-hour radiation treatment option for...
News | Brachytherapy Systems, Women's Healthcare | April 20, 2016
Cianna Medical Inc. announced new clinical data evaluating the Savi Scout breast localization and surgical guidance...
Overlay Init